Eli Lilly and Company has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use $(CHMP)$ has issued a positive opinion recommending donanemab for the treatment of early symptomatic Alzheimer's disease. This recommendation is aimed at adults with confirmed amyloid pathology who are apolipoprotein E ε4 (ApoE4) heterozygotes or non-carriers. The European Commission is expected to make a final regulatory decision on donanemab in the coming months. This development is based on encouraging clinical trial data demonstrating donanemab's potential to slow cognitive and functional decline, marking a significant milestone in Alzheimer's treatment efforts across Europe.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.